Eledon Pharmaceuticals, Inc. (ELDN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinELDN / S&P 27.92% / 15.20% |
LoseELDN / S&P ELDN unavailable / 15.00% |
LoseELDN / S&P -1237.50% / 50.40% |
| 2026-Q11/3 |
WinELDN / S&P 103.97% / -4.33% |
LoseELDN / S&P ELDN unavailable / 11.30% |
LoseELDN / S&P 8.45% / 27.70% |
| 2025-Q40/3 |
LoseELDN / S&P -41.70% / 2.65% |
LoseELDN / S&P ELDN unavailable / 9.00% |
LoseELDN / S&P -63.38% / 13.40% |
| 2025-Q30/3 |
LoseELDN / S&P -4.43% / 8.12% |
LoseELDN / S&P ELDN unavailable / 4.61% |
LoseELDN / S&P -105.12% / 13.45% |
| 2025-Q20/3 |
LoseELDN / S&P -20.06% / 10.94% |
LoseELDN / S&P ELDN unavailable / 4.83% |
LoseELDN / S&P -102.68% / 10.63% |
| 2025-Q10/3 |
LoseELDN / S&P -17.72% / -4.27% |
LoseELDN / S&P ELDN unavailable / 4.98% |
LoseELDN / S&P -85.21% / 10.57% |
| 2024-Q41/3 |
WinELDN / S&P 65.46% / 2.41% |
LoseELDN / S&P ELDN unavailable / 5.25% |
LoseELDN / S&P -70.17% / 6.15% |
| 2024-Q30/3 |
LoseELDN / S&P -5.68% / 5.89% |
LoseELDN / S&P ELDN unavailable / 5.89% |
LoseELDN / S&P -62.96% / 6.11% |
| 2024-Q21/3 |
WinELDN / S&P 28.16% / 4.28% |
LoseELDN / S&P ELDN unavailable / 5.38% |
LoseELDN / S&P -64.14% / 5.12% |
| 2024-Q11/3 |
WinELDN / S&P 14.44% / 10.56% |
LoseELDN / S&P ELDN unavailable / 5.71% |
LoseELDN / S&P -22.83% / 5.59% |
| 2023-Q41/3 |
WinELDN / S&P 31.39% / 11.69% |
LoseELDN / S&P ELDN unavailable / 6.81% |
LoseELDN / S&P -22.73% / 7.78% |
| 2023-Q32/3 |
WinELDN / S&P 0.00% / -3.27% |
LoseELDN / S&P ELDN unavailable / 7.52% |
WinELDN / S&P 196.25% / -5.03% |
| 2023-Q21/3 |
LoseELDN / S&P -41.95% / 8.74% |
LoseELDN / S&P ELDN unavailable / 9.50% |
WinELDN / S&P 219.62% / -8.57% |
| 2023-Q11/3 |
LoseELDN / S&P 3.51% / 7.50% |
LoseELDN / S&P ELDN unavailable / 10.77% |
WinELDN / S&P 153.88% / -15.69% |
| 2022-Q40/3 |
LoseELDN / S&P -17.39% / 7.56% |
LoseELDN / S&P ELDN unavailable / 11.88% |
LoseELDN / S&P ELDN unavailable / -17.99% |
| 2022-Q31/3 |
WinELDN / S&P 13.11% / -4.88% |
LoseELDN / S&P ELDN unavailable / 13.47% |
LoseELDN / S&P ELDN unavailable / -1.41% |
| 2022-Q20/3 |
LoseELDN / S&P -38.07% / -16.10% |
LoseELDN / S&P ELDN unavailable / 13.71% |
LoseELDN / S&P ELDN unavailable / 11.04% |
| 2022-Q10/3 |
LoseELDN / S&P -10.66% / -4.60% |
LoseELDN / S&P ELDN unavailable / 15.97% |
LoseELDN / S&P ELDN unavailable / 42.23% |
| 2021-Q40/3 |
LoseELDN / S&P -28.64% / 11.03% |
LoseELDN / S&P ELDN unavailable / 15.00% |
LoseELDN / S&P ELDN unavailable / 96.40% |
| 2021-Q30/3 |
LoseELDN / S&P -21.87% / 0.58% |
LoseELDN / S&P ELDN unavailable / 10.77% |
LoseELDN / S&P ELDN unavailable / 69.42% |
| 2021-Q20/3 |
LoseELDN / S&P -26.07% / 8.55% |
LoseELDN / S&P ELDN unavailable / 6.58% |
LoseELDN / S&P ELDN unavailable / 51.81% |
| 2021-Q10/3 |
LoseELDN / S&P -30.52% / 6.17% |
LoseELDN / S&P ELDN unavailable / -1.06% |
LoseELDN / S&P ELDN unavailable / 7.39% |
| 2020-Q40/3 |
LoseELDN / S&P -9.94% / 12.15% |
LoseELDN / S&P ELDN unavailable / -3.72% |
LoseELDN / S&P ELDN unavailable / -33.42% |
| 2020-Q31/3 |
WinELDN / S&P 107.42% / 8.93% |
LoseELDN / S&P ELDN unavailable / -2.04% |
LoseELDN / S&P ELDN unavailable / -27.10% |
| 2020-Q20/3 |
LoseELDN / S&P 17.44% / 20.54% |
LoseELDN / S&P ELDN unavailable / -0.46% |
LoseELDN / S&P ELDN unavailable / -27.11% |
| 2020-Q10/3 |
LoseELDN / S&P -32.76% / -19.60% |
LoseELDN / S&P ELDN unavailable / 3.47% |
LoseELDN / S&P ELDN unavailable / -14.75% |
| 2019-Q40/3 |
LoseELDN / S&P -6.45% / 9.07% |
LoseELDN / S&P ELDN unavailable / 5.36% |
LoseELDN / S&P ELDN unavailable / 2.99% |
| 2019-Q30/3 |
LoseELDN / S&P -38.61% / 1.70% |
LoseELDN / S&P ELDN unavailable / 5.02% |
LoseELDN / S&P ELDN unavailable / 0.21% |
| 2019-Q20/3 |
LoseELDN / S&P -74.88% / 4.30% |
LoseELDN / S&P ELDN unavailable / 6.64% |
LoseELDN / S&P ELDN unavailable / 8.65% |
| 2019-Q11/3 |
WinELDN / S&P 151.25% / 13.65% |
LoseELDN / S&P ELDN unavailable / 8.12% |
LoseELDN / S&P ELDN unavailable / 14.29% |
| 2018-Q40/3 |
LoseELDN / S&P -65.74% / -13.52% |
LoseELDN / S&P ELDN unavailable / 9.05% |
LoseELDN / S&P ELDN unavailable / 18.23% |
| 2018-Q30/3 |
LoseELDN / S&P -33.29% / 7.71% |
LoseELDN / S&P ELDN unavailable / 10.21% |
LoseELDN / S&P ELDN unavailable / 19.06% |
| 2018-Q21/3 |
WinELDN / S&P 38.89% / 3.43% |
LoseELDN / S&P ELDN unavailable / 9.03% |
LoseELDN / S&P ELDN unavailable / 14.46% |
| 2018-Q11/3 |
WinELDN / S&P 24.14% / -0.76% |
LoseELDN / S&P ELDN unavailable / 7.68% |
LoseELDN / S&P ELDN unavailable / 12.46% |
| 2017-Q40/3 |
LoseELDN / S&P -22.07% / 6.64% |
LoseELDN / S&P ELDN unavailable / 7.03% |
LoseELDN / S&P ELDN unavailable / 13.82% |
| 2017-Q30/3 |
LoseELDN / S&P -10.94% / 4.48% |
LoseELDN / S&P ELDN unavailable / 5.68% |
LoseELDN / S&P ELDN unavailable / 17.57% |
| 2017-Q20/3 |
LoseELDN / S&P -22.25% / 3.09% |
LoseELDN / S&P ELDN unavailable / 4.83% |
LoseELDN / S&P ELDN unavailable / 17.74% |
| 2017-Q10/3 |
LoseELDN / S&P -14.52% / 6.07% |
LoseELDN / S&P ELDN unavailable / 3.67% |
LoseELDN / S&P ELDN unavailable / 13.32% |
| 2016-Q40/3 |
LoseELDN / S&P -36.08% / 3.82% |
LoseELDN / S&P ELDN unavailable / 2.09% |
LoseELDN / S&P ELDN unavailable / 7.05% |
| 2016-Q30/3 |
LoseELDN / S&P -72.23% / 3.85% |
LoseELDN / S&P ELDN unavailable / 0.20% |
LoseELDN / S&P ELDN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ELDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 28.19% | 20.78% |
| Annualized return | 28.19% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ELDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -59.66% | 83.14% |
| Annualized return | -16.60% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ELDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.10% | 319.30% |
| Annualized return | -32.73% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |